Veradermics

Veradermics, Incorporated is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United States. The company's lead product candidate, VDPHL01, is a proprietary extended-release oral minoxidil formulation being developed as the first oral, non-hormonal treatment for both men and women with pattern hair loss. VDPHL01 uses gel matrix extended-release technology designed to maximize minoxidil's efficacy while minimizing cardiac side effects by avoiding the high peak concentrations of immediate-release formulations. The company has no approved products or revenue and is currently conducting multiple registration-directed Phase 2/3 and Phase 3 clinical trials. Veradermics completed its IPO in February 2026 and trades on the NYSE under the ticker MANE. Its VDPHL01 patent portfolio extends through at least 2043. Updated Aug 11, 2026